In the summer of 2024, a ten-month-old baby in Gaza was partly paralyzed by polio — the territory's first case in 25 years. Two years earlier, a young man in Rockland County, New York, lost the ability to walk after contracting the virus — the first paralytic polio case in the United States in nearly a decade. Around the same time, UK health officials declared a national incident after poliovirus was detected in London's sewage system.
These are not stories from the 1950s. They are headlines from the last three years.
Polio was supposed to be gone by now. In 1988, the World Health Assembly launched the Global Polio Eradication Initiative with the explicit goal of wiping the virus off the planet by the year 2000, the way humanity had eliminated smallpox a decade earlier. Cases did plummet — from an estimated 350,000 per year in 1988 to fewer than 100 wild cases in recent years. But total eradication has remained maddeningly out of reach.
The reasons are complex: wars that destroy health infrastructure, militant groups that block vaccination campaigns, the paradoxical risks of the very vaccine that saved millions, and a global population that increasingly wonders whether polio is still worth worrying about. It is. And understanding why requires looking at the virus itself, the remarkable vaccines we have, and the geopolitical forces that keep getting in the way.
What Polio Actually Does to the Body
Poliovirus is an enterovirus that spreads through the fecal-oral route — primarily through contaminated water in areas with poor sanitation, though it can also pass through respiratory droplets. Once ingested, it replicates in the throat and intestines before potentially invading the central nervous system.
Here is the part that makes polio so insidious: the overwhelming majority of infections produce no symptoms at all. About 72% of people infected with poliovirus are completely asymptomatic — they feel fine, go about their lives, and unknowingly shed the virus in their stool for weeks, silently spreading it to others.
Of the remaining cases, roughly 25% experience what doctors call "abortive poliomyelitis" — a mild illness resembling the flu that resolves within days. Symptoms include fever, sore throat, headache, fatigue, and sometimes nausea and vomiting. Most people recover completely and never know they had polio.
In approximately 1-2% of infections, the virus causes nonparalytic aseptic meningitis — inflammation of the membranes surrounding the brain and spinal cord. This presents with severe headache, neck stiffness, fever, and vomiting, but typically resolves without permanent damage.
The feared outcome — paralytic poliomyelitis — occurs in fewer than 1% of infections, but the numbers are misleading in their apparent smallness. When the virus invades motor neurons in the spinal cord or brainstem, it destroys the nerve cells that control muscles. The resulting paralysis can affect the legs (most commonly), arms, respiratory muscles, or any combination. In spinal polio, weakness is typically asymmetric and develops rapidly, often reaching maximum severity within hours. In bulbar polio, the virus attacks the brainstem, compromising the ability to swallow, speak, and — critically — breathe.
No Cure, No Antiviral: Why Prevention Is Everything
There is no antiviral treatment for polio. This is not a funding gap or a research failure — it is a fundamental reality of how the virus causes damage. By the time paralysis develops, the motor neurons are already destroyed. No drug can regenerate dead nerve cells. Treatment is entirely supportive: physical therapy, mechanical ventilation for those who cannot breathe, pain management, and long-term rehabilitation.
The iron lung — the iconic metal cylinder that breathed for polio patients by creating negative pressure around the chest — was not a treatment. It was life support. Modern intensive care units have replaced it with positive-pressure ventilators that are more effective and portable, but the underlying problem is the same: once the virus has destroyed the neurons that control your diaphragm, something else has to breathe for you.
This is why polio vaccination is not merely recommended — it is the entire strategy. Without a cure, every effort against polio must focus on preventing infection in the first place. And for over six decades, two types of vaccines have been doing exactly that with remarkable effectiveness.
The Two Polio Vaccines: How They Work and Why Both Matter
The story of polio vaccination is really the story of two complementary approaches, each with distinct advantages and trade-offs that have shaped global eradication strategy for decades.
Inactivated Polio Vaccine (IPV) — The Salk Vaccine
Developed by Jonas Salk and licensed in 1955, the inactivated polio vaccine contains killed poliovirus. Administered by injection, it stimulates the immune system to produce antibodies against all three poliovirus serotypes (types 1, 2, and 3) without any risk of causing the disease. IPV provides excellent protection against paralytic polio — the vaccinated person's immune system will neutralize the virus before it can reach the nervous system.
IPV is the standard vaccine used in high-income countries including the United States, Canada, Australia, and most of Europe. It requires trained healthcare workers and sterile injection equipment, and it is more expensive than oral vaccine, but it has one critical advantage: it carries zero risk of causing vaccine-derived polio.
However, IPV has a significant limitation: it primarily generates systemic (blood-based) immunity rather than mucosal immunity in the gut. This means a person vaccinated with IPV alone who encounters wild poliovirus will be protected from paralysis but can still carry and shed the virus in their intestines, potentially spreading it to unvaccinated contacts.
Oral Polio Vaccine (OPV) — The Sabin Vaccine
Developed by Albert Sabin and introduced in the early 1960s, the oral polio vaccine contains live but weakened (attenuated) poliovirus. It is administered as drops in the mouth — no needles, no trained medical professionals required, and it costs a fraction of IPV. These practical advantages made OPV the backbone of global eradication efforts, particularly in low-resource settings.
OPV replicates in the gut, mimicking a natural infection and generating robust mucosal immunity. This means OPV-vaccinated individuals not only resist paralysis but also resist intestinal infection and viral shedding. In communities with high OPV coverage, this gut-level immunity creates a barrier that effectively stops the virus from circulating — protecting even unvaccinated individuals through herd immunity.
OPV can be administered by volunteers with minimal training, making it ideal for mass vaccination campaigns in remote areas, conflict zones, and countries with limited healthcare infrastructure. Teams can go door-to-door, vaccinating children in minutes.
The Paradox: When the Vaccine Itself Becomes the Problem
OPV's greatest strength — its use of a live, attenuated virus — is also the source of its most troubling weakness.
Because OPV contains a weakened but living virus, that virus replicates in the vaccinated child's gut and is shed in stool for several weeks. In communities with adequate sanitation and high vaccination rates, this is actually beneficial: the shed virus acts as a natural booster, passively "vaccinating" close contacts. But in areas with low vaccination coverage and poor sanitation, something dangerous can happen.
As the attenuated vaccine virus passes from person to person in an under-immunized community, it continues to replicate and mutate. Over the course of roughly 12-18 months of uncontrolled circulation, the virus can accumulate enough genetic changes to revert to a form that can cause paralysis. This is known as a circulating vaccine-derived poliovirus, or cVDPV.
The numbers tell a sobering story. While wild poliovirus cases have dropped to double digits per year, vaccine-derived poliovirus cases have surged in many regions. In some recent years, cVDPV cases have actually outnumbered wild polio cases globally. This is the paradox: the tool that brought humanity to the brink of eradicating polio is itself generating new outbreaks in the most vulnerable communities.
The mechanism is well understood. The type 2 poliovirus component of OPV is particularly prone to reversion because the genetic changes that attenuate it are relatively unstable. Wild type 2 poliovirus was declared eradicated in 2015 — the last natural case was detected in 1999. Yet type 2 vaccine-derived poliovirus remains a persistent problem precisely because the type 2 OPV component keeps seeding new outbreaks in under-immunized populations.
The Switch: A Global Gamble That Did Not Go as Planned
Recognizing the type 2 problem, the Global Polio Eradication Initiative orchestrated one of the most ambitious logistical operations in public health history: the synchronized switch from trivalent OPV (containing all three types) to bivalent OPV (containing only types 1 and 3) across 155 countries in April 2016.
The logic was straightforward: since wild type 2 was eradicated, continuing to use the type 2 OPV component was creating more cases than it was preventing. Remove type 2 from the oral vaccine, add IPV to routine immunization to maintain type 2 immunity, and the cVDPV2 problem would fade as the last vaccine-derived viruses burned through remaining susceptible populations.
It did not work as planned. The switch left a growing cohort of children with reduced immunity to type 2 poliovirus — particularly in countries where IPV introduction was delayed or coverage was inadequate. Into this immunity gap, existing cVDPV2 strains continued to circulate and new ones emerged. Outbreaks spread across sub-Saharan Africa, South Asia, and the Middle East.
To contain these outbreaks, the GPEI authorized the use of a novel oral polio vaccine type 2 (nOPV2) — a genetically stabilized version of the type 2 OPV designed to be more resistant to reversion. Granted Emergency Use Listing by the WHO in 2020, nOPV2 has since been deployed in hundreds of millions of doses. Early data suggests it is less likely to revert than the original type 2 Sabin strain, but its long-term performance in complex field conditions is still being evaluated.
Afghanistan and Pakistan: The Last Strongholds of Wild Polio
As of 2024, wild poliovirus type 1 — the only remaining wild strain — is endemic in just two countries: Afghanistan and Pakistan. Every other country in the world has eliminated wild polio transmission. These two nations now represent the final barrier to global eradication, and the barriers are not medical — they are political, cultural, and military.
Afghanistan recorded 23 cases of wild poliovirus in 2024 through October — nearly four times the count for all of 2023. The WHO has expressed concern that even these figures undercount the true burden, given the country's shattered surveillance infrastructure.
The Taliban's relationship with polio vaccination has been consistently hostile. In September 2024, Taliban authorities blocked a planned vaccination campaign just days before it was scheduled to begin. The reasons were multiple: the presence of female vaccinators (which the Taliban oppose on ideological grounds but which is essential for reaching children in households where men cannot enter), and security concerns about door-to-door campaigns revealing the locations of Taliban leaders. The Taliban proposed fixed-site vaccination points at mosques and health centers as an alternative — a model that health experts consider far less effective at reaching every child.
Pakistan faces a similar but distinct set of challenges. Wild polio cases have been rising, driven by population movement across the porous Afghan-Pakistani border, pockets of vaccine refusal fueled by conspiracy theories, and periodic disruptions to campaigns from militancy and security operations. The two countries' polio programs are epidemiologically linked — the virus does not respect borders, and eradication in one country is impossible without eradication in both.
Gaza, London, New York: Polio's Return to 'Polio-Free' Places
The cases in Gaza, London, and New York illustrate a critical point: no country is truly safe from polio as long as the virus exists anywhere.
In Gaza, the poliovirus was detected in sewage samples in mid-2024, and a child was subsequently paralyzed. The conditions for a polio outbreak were textbook: massive displacement, destruction of water and sanitation infrastructure, overcrowded shelters, and disruption of routine childhood vaccination. The WHO launched an emergency vaccination campaign that reached approximately 560,000 children with a first dose of oral vaccine, but the organization acknowledged that ongoing bombardment and displacement were making it impossible to deliver second doses to some children in northern Gaza.
In London, poliovirus was detected in sewage at the Beckton treatment works in 2022 — the facility serves roughly four million people. No paralytic cases were confirmed, but the detection indicated that the virus was circulating in the community. Public health officials launched an urgent booster vaccination campaign targeting children in affected boroughs.
The New York case may be the most alarming for Americans who assumed polio was a relic of history. An unvaccinated young adult in Rockland County developed paralytic polio in June 2022. Subsequent investigation revealed that poliovirus had been silently circulating in the community for months, detected in wastewater from multiple counties. The patient had never been vaccinated — and lived in a community with vaccination rates significantly below the national average.
Why Eradication Has Taken So Long: The Rethink
The original target date for polio eradication was 2000. When that passed, it was revised to 2005. Then 2012. Then 2018. Each deadline has come and gone.
Some experts have begun to question whether complete eradication is achievable with current tools and strategies, or whether the goal should shift to sustained control and eventual eradication once better tools are available.
The challenges are formidable. First, polio's epidemiology works against eradication. Because the vast majority of infections are asymptomatic, the virus can circulate silently for months before a paralytic case alerts authorities. For every child paralyzed, there may be hundreds or thousands of undetected infections in the community. Environmental surveillance — testing sewage for poliovirus — can catch silent circulation, but it is not available everywhere.
Second, the OPV paradox means that the primary tool for eradication in low-resource settings is itself generating new outbreaks, as discussed above. The novel OPV2 may resolve this for type 2, but the fundamental tension between OPV's field advantages and its reversion risk remains for types 1 and 3.
Third, the last pockets of transmission are in the world's most difficult operating environments: active conflict zones, areas under militant control, regions with near-total breakdown of civil infrastructure. These are not problems that more vaccine doses alone can solve.
The WHO's International Health Regulations Emergency Committee has maintained polio as a Public Health Emergency of International Concern (PHEIC) continuously since 2014 — the longest-running PHEIC in history. This designation reflects both the seriousness of the threat and the international community's determination to finish what it started.
Post-Polio Syndrome: The Disease That Comes Back Decades Later
For the millions of people who survived paralytic polio in the pre-vaccine era, the disease did not necessarily end with their initial recovery. Decades later, many survivors develop a condition called post-polio syndrome (PPS) — a poorly understood cluster of symptoms including new or worsening muscle weakness, fatigue, pain, and difficulty with breathing or swallowing.
PPS is estimated to affect 25-40% of polio survivors, typically emerging 15-40 years after the original illness. The prevailing theory is that during the initial infection, the poliovirus destroyed a significant number of motor neurons. Surviving neurons compensated by sprouting new connections to the orphaned muscle fibers — a process called reinnervation. For decades, these overworked neurons managed to maintain muscle function. But eventually, the metabolic strain of supporting far more muscle fibers than they were designed for causes them to deteriorate.
PPS is not a reinfection — the original poliovirus is long gone. It is the delayed consequence of the initial neuronal damage, compounded by the natural aging of an already-compromised nervous system. There is no specific treatment; management focuses on energy conservation, physical therapy, adaptive equipment, and treating symptoms.
The existence of PPS underscores a point that the raw case statistics can obscure: even among those who "recover" from paralytic polio, the disease casts a very long shadow.
The COVID-19 Setback: How the Pandemic Made Polio Worse
The COVID-19 pandemic dealt a severe blow to polio eradication efforts on multiple fronts.
Routine childhood immunization programs were disrupted worldwide as health systems redirected resources to the pandemic response, lockdowns prevented families from reaching vaccination clinics, and supply chains for vaccines were interrupted. The WHO reported that childhood immunization coverage declined significantly during 2020-2021, with polio vaccination among the affected programs. Millions of children missed scheduled doses.
Polio-specific vaccination campaigns — the supplementary immunization activities that go beyond routine doses to reach children in high-risk areas — were suspended in many countries during the early months of the pandemic. These campaigns are the primary tool for responding to outbreaks and maintaining immunity in vulnerable populations, and their interruption created gaps that the virus exploited.
The result was predictable: cVDPV outbreaks expanded in Africa and parts of Asia during 2020-2022. Recovery has been slow. While immunization coverage has begun to rebound, the cohort of children who missed doses during the pandemic remains under-protected, and catching them up requires resources and access that are not always available.
A comprehensive analysis published in The Lancet Infectious Diseases examined the pandemic's impact on polio eradication timelines and concluded that COVID-19 likely pushed complete eradication back by several years.
Vaccine Hesitancy: The Enemy Within
Conflict zones and authoritarian regimes are not the only obstacles to polio eradication. In wealthy, stable countries with abundant healthcare access, vaccine hesitancy poses its own distinct threat.
The Rockland County case in New York was not an isolated importation from a distant country — it was the product of sustained, silent circulation within an under-vaccinated community. The affected area had polio vaccination rates well below the 80-90% threshold needed for herd immunity. Some families had declined vaccination for religious reasons; others had simply not completed the recommended schedule.
Vaccine hesitancy is a spectrum. At one end are those who actively believe vaccines are harmful — a position unsupported by the overwhelming scientific evidence accumulated over six decades and billions of doses. But many vaccine-hesitant parents are not committed anti-vaxxers. They are people overwhelmed by conflicting information, unsure whom to trust, and defaulting to inaction. Others simply do not perceive polio as a real threat — because the vaccines have been so successful that the disease has vanished from collective memory.
This is the paradox of vaccine success: the more effective a vaccine is at eliminating a disease, the less reason people see to get vaccinated, which eventually allows the disease to return. Public health professionals call this the "epidemiologic transition" of vaccine confidence — the point where fear of the vaccine replaces fear of the disease.
For adults in the United States and Europe, the CDC and ECDC provide clear guidance on polio vaccination: most adults who were fully vaccinated as children remain protected and do not need additional doses. However, adults who were never vaccinated or whose vaccination history is unknown should receive a primary series of IPV. Adults traveling to countries where polio is endemic or where outbreaks are occurring should consider a booster dose before travel.
The Endgame Strategy: How the World Plans to Finish This
Despite the setbacks, the global health community has not abandoned the goal of eradication. The GPEI's current Polio Eradication Strategy outlines a multi-pronged approach for the final push.
Interrupting wild poliovirus transmission in Afghanistan and Pakistan remains the top priority. This requires reaching every child with vaccine — including those in insecure areas controlled by militant groups. Strategies include negotiated access (temporary ceasefires for vaccination), use of community health workers trusted by local populations, and integration of polio vaccination with other health services that communities want (like nutritional supplements and deworming).
Stopping cVDPV outbreaks through rapid detection and response, increasingly using nOPV2 for type 2 outbreaks. Environmental surveillance is being expanded to detect circulation before paralytic cases appear.
Strengthening routine immunization to close the immunity gaps that allow outbreaks to take hold. This is arguably the most important long-term strategy: a country with high routine vaccination coverage is essentially fireproof against polio importation.
Planning for OPV cessation — eventually, all use of oral polio vaccine will need to stop worldwide to eliminate the risk of vaccine-derived outbreaks. This will require global coordination on a scale similar to the 2016 switch, but more comprehensive. All countries will need to transition to IPV-only schedules, which means addressing the cost and logistical barriers that make IPV less practical in low-resource settings.
Containment of poliovirus stocks in laboratories and vaccine manufacturing facilities. Even after eradication, poliovirus will continue to exist in research labs and production plants. Strict biosafety measures — and eventually, the development of IPV production methods that do not require handling live wild or Sabin-strain virus — will be essential to prevent reintroduction.
What You Should Know About Your Own Vaccination Status
If you grew up in a high-income country, you were almost certainly vaccinated against polio as a child. In the United States, the standard schedule includes four doses of IPV given at ages 2 months, 4 months, 6-18 months, and 4-6 years. In the UK, polio vaccination is part of the routine childhood immunization schedule with boosters at 3 years 4 months and 14 years.
But there are situations where your vaccination status may not be as secure as you assume.
If you are unsure whether you were fully vaccinated — perhaps you moved between countries as a child, your records were lost, or your family opted out of some vaccinations — the CDC recommends talking to your doctor. If your vaccination history cannot be confirmed, you can safely receive IPV as an adult. There is no harm in receiving additional doses even if you were previously vaccinated.
If you are planning travel to Afghanistan, Pakistan, or any country experiencing a polio outbreak, a booster dose of IPV is recommended before departure, even if you were fully vaccinated as a child. Some countries may require proof of recent polio vaccination for entry.
If you have children, ensuring they are up-to-date on their polio vaccination schedule is one of the simplest and most effective things you can do to protect them. The European Centre for Disease Prevention and Control notes that population immunity must remain high to prevent imported poliovirus from gaining a foothold — and that starts with every individual family maintaining their children's vaccinations.
WatchMyHealth's physician visit tracker can help you log vaccination appointments and keep a record of your family's immunization history. The preventive screening feature takes your health profile into account and can flag when vaccinations or boosters are due — so nothing falls through the cracks.
The Bigger Picture: Why Preventive Health Tracking Matters
Polio is a case study in a broader principle: the diseases that are "conquered" are only conquered for as long as we maintain the systems that conquered them. Vaccination coverage is not a one-time achievement — it is an ongoing commitment that requires vigilance, accurate records, and timely action.
The same principle applies across preventive health. Blood pressure that is well-controlled today can become dangerous if monitoring lapses. Cancer screenings that are up-to-date provide protection; missed screenings create gaps. Metabolic markers like blood glucose and cholesterol tell a story over time, not in a single snapshot.
WatchMyHealth is designed around this principle. The app's preventive health screening system reviews your health profile and generates personalized recommendations for screenings, vaccinations, and check-ups based on established clinical guidelines. The physician visit tracker keeps a record of when you last saw your doctor and what was discussed, so you have a clear picture of your preventive care status.
The data consistently shows that people who systematically track their health engage in more preventive care, catch problems earlier, and have better outcomes. Whether it is ensuring your children's polio vaccinations are complete or scheduling your own age-appropriate screenings, having a system that keeps track means nothing gets forgotten.
The Bottom Line: Polio Is Not Defeated — But It Can Be
Polio eradication is one of the most ambitious public health undertakings in human history, and it remains unfinished. Wild poliovirus type 1 continues to paralyze children in Afghanistan and Pakistan. Vaccine-derived poliovirus outbreaks have emerged in dozens of countries. And the detection of poliovirus in London's sewage and a paralytic case in New York demonstrate that no country with under-vaccinated pockets is truly safe.
But the tools to finish the job exist. The vaccines work. The surveillance systems can detect the virus. The logistics of reaching every child have been proven in hundreds of campaigns across the most challenging environments on earth. What is needed is sustained political will, adequate funding, and the continued commitment of communities to vaccinate their children.
The history of smallpox eradication — achieved in 1980 after a similar decades-long campaign — proves that complete elimination of a human virus is possible. The Global Polio Eradication Initiative has brought humanity closer to that goal than anyone thought possible when the campaign began. The last stretch is the hardest, but giving up is not an option when the alternative is a world where children are paralyzed by a preventable disease.
Check your vaccination records. Talk to your doctor if you are unsure about your status. Make sure your children are up-to-date. And if you are traveling to an area where polio circulates, get a booster. These small actions, multiplied across populations, are what will ultimately consign polio to the history books.
